Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Trump has chosen Jay Bhattacharya from Stanford as the new head of the National Institutes of Health, adding to his controversial cabinet picks. Meanwhile, Eli Lilly is currently the best performing pharmaceutical stock of 2024. The newsletter will be taking a break for Thanksgiving and will return on December 2nd with more biopharma news. In other news, PTC has discontinued an ALS asset after a mid-stage failure, BridgeBio's ATTR-CM drug has been approved, Cassava's Alzheimer's drug has failed in Phase III, and Amgen's Maritide did not impress investors. Eli Lilly has seen a significant improvement in its share price this year, while other pharmaceutical companies have not been as fortunate. Additionally, there have been layoffs at Novartis, Recursion, and Kronos. Legal challenges over Lilly's GLP-1 shortages and Sarepta's investment in Arrowhead for RNA drugs are also highlighted.Eli Lilly leads the list of the biggest share movers in the pharmaceutical industry this year, with a significant improvement in its share price. However, other companies like Amgen have faced disappointments, with their weight loss drug Maritide falling short of investor expectations. Sage Therapeutics also suffered setbacks with the discontinuation of its lead candidate Dalzanemdor after clinical failures. Legal challenges over Lilly's GLP-1 shortages have highlighted the FDA's vulnerability post-Chevron deference. In other news, Roche acquires Poseida, Sarepta aims to diversify its pipeline with RNA drugs, and Trump's cabinet picks raise uncertainty in the biopharma environment. Novartis CEO promises more deals, while companies like Novartis, Recursion, and Kronos have announced layoffs. Subscribe for more relevant updates from BioSpace.